CytoDyn Inc. (CYDY)
OTCMKTS: CYDY · Delayed Price · USD
0.141
-0.001 (-0.35%)
Jul 26, 2024, 3:59 PM EDT - Market closed
CytoDyn Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
149.26M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 48.86B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
CYDY News
- 17 days ago - CytoDyn Announces Settlement with Amarex Clinical Research LLC - GlobeNewsWire
- 4 weeks ago - CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024 - GlobeNewsWire
- 2 months ago - CytoDyn to Host Webcast to Provide Company Update - GlobeNewsWire
- 2 months ago - May 2024 Letter to Shareholders - GlobeNewsWire
- 5 months ago - CytoDyn Announces FDA Has Lifted Clinical Hold - GlobeNewsWire
- 6 months ago - CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma - GlobeNewsWire
- 6 months ago - CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO - GlobeNewsWire
- 6 months ago - SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CytoDyn Inc. (OTC: CYDY) - PRNewsWire